GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical stage biopharmaceutical company that focuses on the development of drugs to treat Alzheimer's CNS diseases and other types of cancer which have significant unmet medical needs. According to GeoInvesting, Anavex is merely a "penny stock promotional campaign" that "should end badly" According to GeoInvesting, Anavex is "being touted as the potential next biggest thing in biotech." However, the company is "perfectly positioned as just another pump and dump that will likely have little to no residual equity value as the story plays out."GeoInvesting noted that it has found various promotional materials that promise subscribers gains of more than 2,000 percent. Another website indicates that a penny stock newsletter was paid $200,000 to promote the stock in October 2015.Unsuccessful Business ModelGeoInvesting further stated that while the Alzheimer's Disease is an "enormous" market, the space is already full with the "major" drug companies, such as Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Eli Lilly and Co (NYSE: LLY) are active in the space. These companies are backed by tens of thousands of employees and R&D budgets in the hundreds of millions of dollars.Meanwhile, Anavex Life Sciences is a "six person company with very limited clinical data and limited resources.""In the case of who is going to develop the breakthrough in Alzheimer's disease first, we are going to put our money on somebody other than Anavex," the report stated.